Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    17208639 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Trastuzumab in Treating Women With Primary Breast Cancer
Condition: Breast Cancer
Interventions: Biological: trastuzumab;   Procedure: adjuvant therapy
2 Recruiting T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy
Condition: Gastric Cancer
Interventions: Drug: Trastuzumab;   Drug: Capecitabine;   Drug: Oxaliplatin
3 Not yet recruiting Observation of Medical Treatments in MBC HER2-negative Patients
Condition: Metastatic Breast Cancer
Intervention: Other: Observation of treatment management

Indicates status has not been verified in more than two years